Lonza's new medium boosts and optimizes AAV production in insect cells

23 Mar 2020

The TheraPEAK SfAAV Medium is specifically designed to support the development of safe, scalable, gene therapies.

In an effort to help biotechnology companies to fast track the development of safe gene therapies to treat a range of life-threatening conditions, Lonza has launched the first chemically defined, non-animal origin medium designed to increase Adeno Associated Virus (AAV) production in Spodoptera Fuigiperda Sf9 insect cells.

Lonza's new medium boosts and optimizes AAV production in insect cells
Lonza's TheraPEAK SfAAV Medium for AAV production in SF9 cells.

The new high-performance medium accelerates cell growth, increases productivity, and reduces process variability and costs, expediting time-to-market for safe, scalable, life-saving gene therapies.

Gene therapy holds great promise for the treatment of rare disorders and diseases, and viral vectors are commonly used to facilitate the delivery of the gene of interest into patient cells.

AAV has been established as a viral vector of choice, due to not replicating in patients, thus posing a lower health risk. Owing to their ability to be grown at high densities, the Sf9 insect cells are ideal for use as hosts for the production of large AAV quantities. To date, however, translational scientists and researchers have been challenged with the lack of a medium dedicated to AAV production in Sf9 insect cells.

The company reports that its TheraPEAK SfAAV Medium provides a cost and time-efficient solution for the production of AAV in Sf9 insect cells. Allowing for rapid cell growth, the TheraPEAK SfAAV Medium reduces processing time significantly, enabling cell infection one day earlier than similar media available on the market, and boosting laboratory performance.

Due to its chemically defined nature, the new hydrolysate free medium produces AAV that requires less purification, further decreasing the overall processing time and minimizing labour requirements. Furthermore, the TheraPEAK SfAAV Medium supports consistent cell growth throughout all phases of the culturing process, considerably reducing process variability.

As a chemically defined, non-animal origin product, the TheraPEAK SfAAV Medium is safer to use than media containing animal or human components, thereby facilitating regulatory compliance. Additionally, the medium is supplied with a US Food and Drug Administration drug master file, alleviating the relevant preparation and submission burden.

Read More

Related news

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

23 Jun 2020

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

Read more 
CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

23 Jun 2020

The amended manufacturing agreement, which originally specified CordenPharma facilities Switzerland, now extends to the CDMOs France and US sites.

Read more 
TraceLink announces results from FDA DSCSA Pilot Program

TraceLink announces results from FDA DSCSA Pilot Program

23 Jun 2020

Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.

Read more 
FDA approves new Dupixent prefilled pen

FDA approves new Dupixent prefilled pen

23 Jun 2020

The prefilled pen supports more convenient self-administration for patients with chronic type 2 inflammatory diseases.

Read more 
Piramal acquires solid oral dosage drug product facility from G&W Laboratories

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

22 Jun 2020

The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.

Read more 
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

22 Jun 2020

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
Pharma packaging companies commit to supply for COVID-19 fight

Pharma packaging companies commit to supply for COVID-19 fight

16 Jun 2020

Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.

Read more 
BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology

BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology

16 Jun 2020

Novel platform initially focussed on high-resolution industrial-scale processing of therapeutic mRNA.

Read more 
Pharma’s supply chain prepares for the ‘next normal’ in a post-COVID-19 world

Pharma’s supply chain prepares for the ‘next normal’ in a post-COVID-19 world

15 Jun 2020

Supply chain executives request greater visibility and transparency, especially at the supplier and manufacturer level.

Read more